DOI: 10.1055/s-00050348

Indian Journal of Medical and Paediatric Oncology

References

Zeiser R, von Bubnoff N, Butler J. et al; REACH2 Trial Group.
Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease.

N Engl J Med 2020;
382 (19) 1800-1810

Download Bibliographical Data

Access:
Access: